PMID- 34149879
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210622
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 22
IP  - 2
DP  - 2021 Aug
TI  - Protective role and molecular mechanism of action of Nesfatin-1 against high 
      glucose-induced inflammation, oxidative stress and apoptosis in retinal 
      epithelial cells.
PG  - 833
LID - 10.3892/etm.2021.10265 [doi]
LID - 833
AB  - Diabetic retinopathy (DR) is a major complication of diabetes mellitus that may 
      cause severe visual impairment. It has been reported that the levels of 
      nesfatin-1 in the serum and vitreous humor were negatively correlated with DR; 
      however, its role in DR has not been fully elucidated. Therefore, the present 
      study was performed to investigate the effect of nesfatin-1 on high 
      glucose-treated human retinal epithelial cells (ARPE-19) and explore the 
      underlying mechanism. The effects of nesfatin-1 on cell viability, inflammation, 
      oxidative stress and apoptosis were examined under high glucose conditions. The 
      Cell Counting Kit-8 assay was used to determine cell viability. The levels of 
      inflammatory cytokines were evaluated using ELISA kits. The reactive oxygen 
      species and malondialdehyde content was estimated using commercial assay kits. 
      Flow cytometry was performed to detect apoptotic cells and western blot analysis 
      was employed to evaluate the expression of apoptosis-associated proteins. 
      Moreover, the levels of NF-kappaB, NACHT, LRR and PYD domains-containing protein 3 
      (NLRP3) and high-mobility group protein B1 (HMGB1) were determined via western 
      blot analysis. The results revealed that nesfatin-1 enhanced cell viability and 
      suppressed inflammation, oxidative stress and apoptosis in the presence of high 
      glucose concentration. Moreover, the activation of the NF-kappaB/NLRP3 inflammasome 
      signaling and the expression of HMGB1 were inhibited by nesfatin-1. Furthermore, 
      HMGB1 overexpression partially abrogated the inactivation of the NF-kappaB/NLRP3 
      inflammasome pathway caused by nesfatin-1. Taken together, these findings 
      demonstrated that nesfatin-1 inhibited the activation of the NF-kappaB/NLRP3 
      inflammasome signaling via modulating HMGB1 and exerted a protective effect on 
      ARPE-19 cells against high glucose-induced inflammation, oxidative stress and 
      apoptosis.
CI  - Copyright: (c) Sun et al.
FAU - Sun, Haiyan
AU  - Sun H
AD  - Ophthalmology Department, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050051, P.R. China.
FAU - Zhao, Huahui
AU  - Zhao H
AD  - Ophthalmology Department, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050051, P.R. China.
FAU - Yan, Zhipeng
AU  - Yan Z
AD  - Ophthalmology Department, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050051, P.R. China.
FAU - Liu, Xiaokun
AU  - Liu X
AD  - Ophthalmology Department, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050051, P.R. China.
FAU - Yin, Pengfei
AU  - Yin P
AD  - Ophthalmology Department, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050051, P.R. China.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Ophthalmology Department, The Third Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050051, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20210603
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC8200809
OTO - NOTNLM
OT  - LRR and PYD domains-containing protein 3
OT  - NACHT
OT  - diabetic retinopathy
OT  - high glucose
OT  - high-mobility group protein B1
OT  - nesfatin-1
COIS- The authors declare that they have no competing interests.
EDAT- 2021/06/22 06:00
MHDA- 2021/06/22 06:01
PMCR- 2021/06/03
CRDT- 2021/06/21 05:53
PHST- 2020/09/11 00:00 [received]
PHST- 2021/01/21 00:00 [accepted]
PHST- 2021/06/21 05:53 [entrez]
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2021/06/22 06:01 [medline]
PHST- 2021/06/03 00:00 [pmc-release]
AID - ETM-0-0-10265 [pii]
AID - 10.3892/etm.2021.10265 [doi]
PST - ppublish
SO  - Exp Ther Med. 2021 Aug;22(2):833. doi: 10.3892/etm.2021.10265. Epub 2021 Jun 3.